Multicenter, Prospective and Open-label Clinical Trial to Evaluate the Viability, Performance and Safety of ex Vivo Normothermic Perfusion in Kidney Transplantation From DCD and DBD Donors.

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A multicenter, prospective and open-label clinical investigation to evaluate the viability, performance and safety of ex vivo normothermic perfusion in kidney transplantation from DCD and DBD donors.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients aged 18 years and older

• Patients undergoing renal replacement therapy by means of dialysis and included in the waiting list for renal transplantation in their respective site.

• Candidates to receive a first or second renal transplant from (i) a Maastricht type III (Maastricht classification) controlled DCD donor or (ii) a DBD donor aged 70 years or older.

• Patients that have given informed consent in written form before their inclusion in the study. In case of compromised mental capacity, the approval and signature of a legal guardian will be required.

• Patients compliant with the requirements of the study and without impediments to follow the instructions throughout the 1-year duration of the study.

• Patients that meet the acceptance criteria for kidney transplant recipients established in the clinical site in agreement with usual clinical practice.

Locations
Other Locations
Spain
Miguel Servet University Hospital
RECRUITING
Zaragoza
Contact Information
Primary
Pedro Moreo Calvo, PhD
info@ebersmedical.com
+34 876 013 826
Time Frame
Start Date: 2023-12-14
Estimated Completion Date: 2027-12
Participants
Target number of participants: 100
Treatments
Experimental: Experimental group
Ex vivo normothermic perfusion (EVNP) of the graft with the Ark Kidney System
Active_comparator: Historical control group
Nonrandomized historical control group formed by patients transplanted without ex vivo normothermic perfusion (EVNP) in the period Sept 2015-Sept 2020, selected by retrospective matching.
Related Therapeutic Areas
Sponsors
Leads: Ebers Medical Technology, S.L.

This content was sourced from clinicaltrials.gov